Orthobiologics developer and provider OssDsign has appointed Mark Waugh as its new CEO, effective January 1, 2026. He succeeds Morten Hennevald, who will step down from his role as CEO at the end of the year.

Waugh was most recently senior vice president, commercial at Medacta USA, part of Swiss company Medacta International. He also brings over two decades of leadership experience from organizations like Smith+Nephew and Medtronic Sofamor Danek.

OssDsign said Waugh’s appointment builds on the foundations laid by the company since 2019 and allows a stronger presence and focus on the U.S. market. He will be based at the company’s U.S. office in Maryland and his home office in Indiana.

“We look forward to Mark Waugh leading OssDsign in its next phase of growth and development,” said OssDsign chairman Simon Cartmell. “Drawing on his extensive experience in major orthopedic sectors, specifically in spine, and his track record of driving commercial execution as a senior executive working for two leading European orthopedic companies, he is exceptionally well-positioned to drive adoption with surgeons and distributors, bring benefit to thousands more patients as a result, and create long-term value for shareholders.”

Since launching OssDsign Catalyst in the U.S. in August 2021 and subsequently focusing exclusively on orthobiologics, OssDsign has experienced strong double-digit growth.

“I am honored to join OssDsign and thankful for the board’s confidence in me,” Waugh said. “I am excited about leading our dedicated employees in the company’s next growth phase. I look forward to leveraging my experience to deliver exceptional outcomes for all our stakeholders.”